Cytokinetics Inc (NAS:CYTK)
$ 59.23 -0.91 (-1.51%) Market Cap: 6.21 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Cytokinetics Inc To Discuss Omecamtiv Mecarbil Regulatory Update Call Transcript

Mar 01, 2023 / 01:30PM GMT
Release Date Price: $43.11 (-0.58%)
Operator

Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call. At this time, I'd like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Diane Weiser, Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Good morning, and thanks for joining us on the call today to discuss the regulatory update related to omecamtiv mecarbil. On the call with me today are Robert Blum, President and Chief Executive Officer, who will make opening remarks; and Fady Malik, EVP of Research and Development; Andrew Callos, EVP and Chief Commercial Officer; and Ching Jaw, SVP and Chief Financial Officer, who will participate in our Q&A.

Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot